|
1
|
Shimasaki T, Seekatz A, Bassis C, Rhee Y,
Yelin RD, Fogg L, Dangana T, Cisneros EC, Weinstein RA, Okamoto K,
et al: Increased relative abundance of Klebsiella pneumoniae
carbapenemase-producing Klebsiella pneumoniae within the gut
microbiota is associated with risk of bloodstream infection in
long-term acute care hospital patients. Clin Infect Dis.
68:2053–2059. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Navon-Venezia S, Kondratyeva K and
Carattoli A: . Klebsiella pneumoniae: A major worldwide
source and shuttle for antibiotic resistance. FEMS Microbiol Rev.
41:252–275. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lee BY, Bartsch SM, Wong KF, McKinnell JA,
Slayton RB, Miller LG, Cao C, Kim DS, Kallen AJ, Jernigan JA and
Huang SS: The potential trajectory of carbapenem-resistant
Enterobacteriaceae, an emerging threat to health-care
facilities, and the impact of the centers for disease control and
prevention toolkit. Am J Epidemiol. 183:471–479. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Braun SD, Dorneanu OS, Vremeră T, Reißig
A, Monecke S and Ehricht R: Carbapenemase-producing
Enterobacteriaceae: A 2-year surveillance in a hospital in
Iaşi, Romania. Future Microbiol. 11:391–401. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bradford PA: Extended-spectrum
beta-lactamases in the 21st century: Characterization,
epidemiology, and detection of this important resistance threat.
Clin Microbiol Rev. 14:933–951. 2001.PubMed/NCBI View Article : Google Scholar
|
|
6
|
European Committee on Antimicrobial
Susceptibility Testing (EUCAST): EUCAST guidelines for detection of
resistance mechanisms and specific resistances of clinical and/or
epidemiological importance. Version 2.01. EUCAST, Sweden, 2017.
https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf.
Accessed Febrary 20, 2021.
|
|
7
|
Pana ZD and Zaoutis T: Treatment of
extended-spectrum β-lactamase-producing Enterobacteriaceae
(ESBLs) infections: What have we learned until now? F1000Res.
7(F1000 Faculty Rev-1347)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Paterson DL and Bonomo RA:
Extended-spectrum beta-lactamases: A clinical update. Clin
Microbiol Rev. 18:657–686. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Miftode E, Dorneanu O, Leca D, Teodor A,
Mihalache D, Filip O and Luca V: Antimicrobial resistance profile
of E. coli and Klebsiella spp. From urine in the
infectious diseases hospital Iaşi. Rev Med Chir Soc Med Nat Iasi.
112:478–482. 2008.PubMed/NCBI(In Romanian).
|
|
10
|
Brolund A, Edquist PJ, Mäkitalo B,
Olsson-Liljequist B, Söderblom T, Wisell KT and Giske CG:
Epidemiology of extended-spectrum β-lactamase-producing
Escherichia coli in Sweden 2007-2011. Clin Microbiol Infect.
20:O344–O352. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rodríguez-Baño J, Alcalá JC, Cisneros JM,
Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G,
Cuenca M, et al: Community infections caused by extended-spectrum
beta-lactamase-producing Escherichia coli. Arch Intern Med.
168:1897–1902. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Maslikowska JA, Walker SA, Elligsen M,
Mittmann N, Palmay L, Daneman N and Simor A: Impact of infection
with extended-spectrum β-lactamase-producing Escherichia
coli or Klebsiella species on outcome and
hospitalization costs. J Hosp Infect. 92:33–41. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Morrissey I, Hackel M, Badal R, Bouchillon
S, Hawser S and Biedenbach D: A review of ten years of the study
for monitoring antimicrobial resistance trends (SMART) from 2002 to
2011. Pharmaceuticals (Basel). 6:1335–1346. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Biehl LM, Schmidt-Hieber M, Liss B,
Cornely OA and Vehreschild MJ: Colonization and infection with
extended spectrum beta-lactamase producing
Enterobacteriaceae in high-risk patients-review of the
literature from a clinical perspective. Crit Rev Microbiol.
42:1–16. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
EUCAST Clinical breakpoints-breakpoints
and guidance, 2018. https://www.eucast.org/clinical_breakpoints/. Accessed
December 10, 2019.
|
|
16
|
Kader AA and Kumar A: Prevalence and
antimicrobial susceptibility of extended-spectrum
beta-lactamase-producing Escherichia coli and Klebsiella
pneumoniae in a general hospital. Ann Saudi Med. 25:239–242.
2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sarojamma V and Ramakrishna V: Prevalence
of ESBL-producing Klebsiella pneumoniae isolates in tertiary
care hospital. ISRN Microbiol. 2011(318348)2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pitout JD and Laupland KB:
Extended-spectrum beta-lactamase-producing
Enterobacteriaceae: An emerging public-health concern.
Lancet Infect Dis. 8:159–166. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Goossens H: MYSTIC Study Group (Europe).
MYSTIC program: Summary of European data from 1997 to 2000. Diagn
Microbiol Infect Dis. 41:183–189. 2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hoşoğlu S, Gündes S, Kolayli F,
Karadenizli A, Demirdağ K, Günaydin M, Altindis M, Caylan R and
Ucmak H: Extended-spectrum beta-lactamases in ceftazidime-resistant
Escherichia coli and Klebsiella pneumoniae isolates
in Turkish hospitals. Indian J Med Microbiol. 25:346–350.
2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xiong Z, Zhu D, Zhang Y and Wang F:
Extended-spectrum beta-lactamase in Klebsiella pneumoniae
and Escherichia coli isolates. Zhonghua Yi Xue Za Zhi.
82:1476–1479. 2002.PubMed/NCBI(In Chinese).
|
|
22
|
Miftode E, Dorneanu O, Badescu A, Ghibu L,
Leca D, Vremera T and Mereuţă A: Emergence of a new group CTX-M
enzyme in Romania and risk factors for extended spectrum
beta-lactamase producing E. coli infections. Rev Med Chir
Soc Med Nat Iasi. 116:477–480. 2012.PubMed/NCBI
|
|
23
|
Anton-Paduraru DT, Miftode EG, Iliescu ML,
Pricop C, Carauleanu A and Boiculese LV: Knowledge of adolescent
girls regarding sexually transmitted diseases a study in a rural
area from North-Eastern Romania. Rev Cercet Interv Soc. 69:143–155.
2020.
|
|
24
|
Costache II, Miftode E, Mitu O and
Aursulesei V: Sex differences in cardiovascular risk factors in a
rural community from North Romania Region. Rev Cercet Interv Soc.
55:204–214. 2016.
|
|
25
|
Platt R, Polk BF, Murdock B and Rosner B:
Risk factors for nosocomial urinary tract infection. Am J
Epidemiol. 124:977–985. 1986.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lee DS, Lee CB and Lee SJ: Prevalence and
risk factors for extended spectrum beta-lactamase-producing
uropathogens in patients with urinary tract infection. Korean J
Urol. 51:492–497. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yilmaz E, Akalin H, Ozbey S, Kordan Y,
Sinirtaş M, Gürcüoglu E, Ozakin C, Heper Y, Mistik R and Helvaci S:
Risk factors in community-acquired/onset urinary tract infections
due to extended-spectrum beta-lactamase-producing Escherichia
coli and Klebsiella pneumoniae. J Chemother. 20:581–585.
2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vading M, Nauclér P, Kalin M and Giske CG:
Invasive infection caused by Klebsiella pneumoniae is a
disease affecting patients with high comorbidity and associated
with high long-term mortality. PLoS One.
13(e0195258)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nguyen ML, Toye B, Kanji S and Zvonar R:
Risk factors for and outcomes of bacteremia caused by
extended-spectrum β-lactamase-producing Escherichia coli and
Klebsiella species at a Canadian tertiary care hospital. Can
J Hosp Pharm. 68:136–143. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Koksal E, Tulek N, Sonmezer MC, Temocin F,
Bulut C, Hatipoglu C, Erdinc FS and Ertem G: Investigation of risk
factors for community-acquired urinary tract infections caused by
extended-spectrum beta-lactamase Escherichia coli and
Klebsiel species. Investig Clin Urol. 60:46–53.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tofas P, Skiada A, Angelopoulou M, Sipsas
N, Pavlopoulou I, Tsaousi S, Pagoni M, Kotsopoulou M, Perlorentzou
S, Antoniadou A, et al: Carbapenemase-producing Klebsiella
pneumoniae bloodstream infections in neutropenic patients with
haematological malignancies or aplastic anaemia: Analysis of 50
cases. Int J Antimicrob Agents. 47:335–339. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Parveen RM, Khan MA, Menezes GA, Harish
BN, Parija SC and Hays JP: Extended-spectrum β-lactamase producing
Klebsiella pneumoniae from blood cultures in Puducherry,
India. Indian J Med Res. 134:392–395. 2011.PubMed/NCBI
|
|
33
|
Ullah F, Malik SA and Ahmed J:
Antimicrobial susceptibility pattern and ESBL prevalence in
Klebsiella pneumoniae from urinary tract infections in the
North-West of Pakistan. Afr J Microbiol Res. 3:676–680. 2009.
|
|
34
|
Abdullah FE, Mushtaq A, Irshad M, Rauf H,
Afzal N and Rasheed A: Current efficacy of antibiotics against
Klebsiella isolates from urine samples-a multi-centric
experience in Karachi. Pak J Pharm Sci. 26:11–15. 2013.PubMed/NCBI
|
|
35
|
Müller-Schulte E, Tuo MN, Akoua-Koffi C,
Schaumburg F and Becker SL: High prevalence of ESBL-producing
Klebsiella pneumoniae in clinical samples from central Côte
d'Ivoire. Int J Infect Dis. 91:207–209. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lautenbach E, Patel JB, Bilker WB,
Edelstein PH and Fishman NO: Extended-spectrum
beta-lactamase-producing Escherichia coli and Klebsiella
pneumoniae: Risk factors for infection and impact of resistance
on on outcomes. Clin Infect Dis. 32:1162–1171. 2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shanthi M and Sekar U: Extended spectrum
beta lactamase producing Escherichia coli and Klebsiella
pneumoniae: Risk factors for infection and impact of resistance
on outcomes. J Assoc Physicians India. 58 (Suppl):S41–S44.
2010.PubMed/NCBI
|
|
38
|
MacVane SH, Tuttle LO and Nicolau DP:
Impact of extended-spectrum β-lactamase-producing organisms on
clinical and economic outcomes in patients with urinary tract
infection. J Hosp Med. 9:232–238. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shamsrizi P, Gladstone BP, Carrara E,
Luise D, Cona A, Bovo C and Tacconelli E: Variation of effect
estimates in the analysis of mortality and length of hospital stay
in patients with infections caused by bacteria-producing
extended-spectrum beta-lactamases: A systematic review and
meta-analysis. BMJ Open. 10(e030266)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Vata A, Hunea IM, Dorneanu O, Harja-Alexa
IA, Plesca C, Leonte-Enache G, Ciocan A, Ghiciuc CM, Esanu I,
Manolache M and Luca CM: Biochemical changes and risk factors in
the prognosis of antibiotics susceptibility in urinary tract
infections. Rev Chim. 70:1822–1825. 2019.
|
|
41
|
Kola A, Maciejewski O, Sohr D, Ziesing S
and Gastmeier P: Clinical impact of infections caused by
ESBL-producing E. coli and K. pneumoniae. Scand J
Infect Dis. 39:975–982. 2007.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Bassetti M, Peghin M and Pecori D: The
management of multidrug-resistant Enterobacteriaceae. Curr
Opin Infect Dis. 29:583–594. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tamma PD, Han JH, Rock C, Harris AD,
Lautenbach E, Hsu AJ, Avdic E and Cosgrove SE: Antibacterial
Resistance Leadership Group. Carbapenem therapy is associated with
improved survival compared with piperacillin-tazobactam for
patients with extended-spectrum β-lactamase bacteremia. Clin Infect
Dis. 60:1319–1325. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli
Y, Paterson DL, Almirante B, Martínez-Martínez L, Oliver A, Calbo
E, Peña C, Akova M, et al: Ertapenem for the treatment of
bloodstream infections due to ESBL-producing
Enterobacteriaceae: A multinational pre-registered cohort
study. J Antimicrob Chemother. 71:1672–1680. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Betriu C, Salso S, Sánchez A, Culebras E,
Gómez M, Rodriguez-Avial I and Picazo JJ: Comparative in vitro
activity and the inoculum effect of ertapenem against
Enterobacteriaceae resistant to extended-spectrum
cephalosporins. Int J Antimicrob Agents. 28:1–5. 2006.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mody RM, Erwin DP, Summers AM, Carrero HA,
Selby EB, Ewell AJ and Moran KA: Ertapenem susceptibility of
extended spectrum beta-lactamase-producing organisms. Ann Clin
Microbiol Antimicrob. 6(6)2007.PubMed/NCBI View Article : Google Scholar
|
